" class="no-js "lang="en-US"> Theator Extends Series A Funding with Additional $24M for a Total of $39.5M - Medtech Alert
Saturday, May 18, 2024

Theator Extends Series A Funding with Additional $24M for a Total of $39.5M

Theator, the creator of Surgical Intelligence, announced today that it has raised $24M in an extension of its Series A funding round. This extension follows an initial $15.5M Series A round announced in February 2021, bringing the round total to $39.5M. The extended funding round was once again led by Insight Partners with support from existing investors including Blumberg Capital, Mayo Clinic, NFX, StageOne Ventures, iAngels, and former Netflix Chief Product Officer Neil Hunt. In addition, new growth investors including iCON and TripActions’ CEO and Co-founder Ariel Cohen joined the round.

The additional investment will be used to continue Theator’s commercial expansion and accelerate the rollout of its Surgical Intelligence Platform in operating rooms and healthcare systems across North America. The series extension comes on the heels of significant commercial traction, including Theator’s expansion into Urology earlier this year.

Theator is pioneering Surgical Intelligence to eliminate the paradigm that where you live determines if you live. Theator’s Surgical Intelligence Platform institutionalizes the routine capture of surgical video data, harnessing AI and computer vision to automatically analyze every operation. Surgical Intelligence generates actionable insights that optimize patient outcomes, ultimately raising the standard of patient care. Theator’s unrivaled library of surgical video and data contains over 30K hours of video, with nearly a billion frames analyzed.

“This funding is a strong vote of confidence in our vision, team, and the field of Surgical Intelligence as the cornerstone of the future of surgery,” said Dr. Tamir Wolf, CEO and Co-founder of Theator. “Surgical Intelligence is already demonstrating significant improvement in surgical quality and safety. It’s thrilling to hear about the impact our partners and collaborators have achieved thus far, and we look forward to this latest investment advancing our mission to transform surgery and alleviate variability and disparity in surgical care worldwide.”

“Theator’s technology has proven to be the critical next step in surgical advancement,” said Brad Fiedler, VP at Insight Partners. “Integrating AI and computer vision into the operating room improves surgical care and is transforming surgery for the better. We’re excited to double down on our investment, especially as Theator’s expertise in AI and computer vision is now enhancing patient outcomes across an ever-growing range of commercial partners.”

“Theator’s Surgical Intelligence Platform is changing the way we as surgeons think about the operating room today,” said Dr. Gerald Fried, former Chair of Surgery at McGill University and past president of the Society of American Gastrointestinal and Endoscopic Surgeons (SAGES).“The Platform surfaces key information embedded within a procedure into a format that is usable by surgeons to enhance the safety, quality, and efficiency of what we do in the operating room. Surgical Intelligence is the future of surgery.”

With this Series A extension, Theator has raised $42.5M to date. Since its initial Series A round last year, Theator has collaborated with Mayo Clinic and partnered with the Canadian Association of General Surgeons (CAGS), adding further prestige to the burgeoning list of innovative medical institutions and surgical societies adopting Surgical Intelligence. Last December, the company was named on CB Insights’ prestigious Digital Health 150 list of the 150 most innovative digital health startups in the world, highlighting industry recognition of Surgical Intelligence as a distinct category for the first time.

People In This Post

Companies In This Post

  1. Eloxx Pharmaceuticals Announces Final Data Assessment from Phase 2 Combination Clinical Trial of ELX-02 in Class 1 Cystic Fibrosis Patients Read more
  2. Verge Genomics Announces Positive Safety and Tolerability Data from the Phase 1 Clinical Trial of VRG50635, a Potential Best-in-Class Therapeutic for All Forms of ALS Read more
  3. DEM BioPharma Appoints Wendy Young, Ph.D., to Scientific Advisory Board Read more
  4. Confo Therapeutics Enters into Research Collaboration for GPCR-Targeting Antibody Discovery with AbCellera Read more
  5. Vyriad Announces Expansion of T-Cell Lymphoma Trial at Mayo Clinic Read more